Sustainability Using Zero-Carbon Biopharma Facilities

The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.

This podcast explores the challenges of and the progress made so far by the biopharma industry toward alternative drug delivering methods for biologic drugs.

Incorporating sustainable practices into process designs as early as possible ensures optimal performance.

Hanns-Christian Mahler and Andrea Allmendinger from ten23 health will discuss some key aspects of biologic drug development and manufacturing.

The company’s intent is to establish Merck Wilmington Biotech as the future United States home for producing Keytruda for US patients.

The company’s exhibitions will be focused in the areas of its pipeline, proprietary capsid engineering, and manufacturing.